The pharmacodynamics and pharmacokinetics of the 5HT(1B/1D)-agonist zolmitriptan in healthy young and elderly men and women

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 3, 1998, Pages 342-353

  Peck, Richard W ^a   Seaber, Emma J ^a   Dixon, Ruth M ^b   Layton, Gary R ^c   Weatherley, Barry C ^f   Jackson, Stephen H D ^f   Rolan, Paul E ^d   Posner, John ^e  

^a GLAXOSMITHKLINE   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d Medeval Ltd   (United Kingdom)

^e Pinewood College Ride   (United Kingdom)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; PLACEBO; ZOLMITRIPTAN; OXAZOLE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; SEROTONIN AGONIST; TRYPTAMINE DERIVATIVE;

ADULT; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; GENDER; HEART RATE; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MIGRAINE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SYSTOLIC BLOOD PRESSURE; VOLUNTEER; AGE; BLOOD PRESSURE; DRUG EFFECT; ELECTROCARDIOGRAPHY; FEMALE; HALF LIFE TIME; MALE; REFERENCE VALUE; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HALF-LIFE; HEART RATE; HUMANS; MALE; OXAZOLES; OXAZOLIDINONES; REFERENCE VALUES; SEROTONIN AGONISTS; SEX FACTORS; TRYPTAMINES;

EID: 0031594170     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90166-7     Document Type: Article

References (31)

1. Goldstein ME, Chen TC. The epidemiology of disabling headache. Adv Neurol 1982;33:377-90.
2. Humphrey P, Feniuk W. Mode of action of the antimigraine drug sumatriptan. Trends Pharmacol Sci 1991;12:444-5.
3. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992;13:307-11.
4. Kaube H, Hoskin K, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood brain barrier disruption. Br J Pharmacol 1993; 109:788-92.
5. 1D receptor agonist 311C90. New Adv Headache Res 1994;4:3-4.
6. Goadsby PJ, Edvinsson L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache 1994;34:394-9.
7. Ferrari MD. The clinical effectiveness of 311C90 in the acute treatment of migraine. Eur Neurol 1996; 36(suppl 2):4-7.
8. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991;31:291-4.
9. 1-like agonist GR43175 in healthy volunteers. Cephalgia 1989; 9(suppl 9):57-62.
10. 1-receptor agonist on central haemodynamics and the coronary circulation. Br J Clin Pharmacol 1992;34:541-6.
11. Seaber E, On N, Phillips S, Churchus R, Posner J, Rolan P. The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. Br J Clin Pharmacol 1996;41:141-7.
12. Dixon R, Gillotin C, Gibbens M, Posner J, Peck RW. The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan in healthy volunteers. Br J Clin Pharmacol 1997;43:273-81.
13. Mercer AJ, Lamb RJ, Posner J. The effects of 311C90, a novel 5HT1D-agonist for the treatment of migraine, lorazepam and placebo on psychometric task performance in healthy volunteers [abstract]. Headache 1995;35:304.
14. Seaber E, On N, Dixon R, Gibbens M, Liptrot J, Chittick G, et al. The absolute bioavailability and metabolic disposition of the novel anti-migraine compound 311C90. Br J Clin Pharmacol 1997;43: 579-87.
15. Martin GR, Dixon R. Pre-clinical and clinical pharmacology of the novel anti-migraine compound 311C90 [abstract]. Headache 1995;35:291.
16. Linet M, Stewart W. Migraine headache: epidemiologic perspectives. Epidemiol Rev 1984;6:107-39.
17. Nolan J, Flapan AD, Goodfield NE, Bloomfield P, Neilson JM, Ewing DJ. Reproducibility of time domain measurement of cardiac parasympathetic activity from ambulatory electrocardiograms [abstract]. J Am Coll Cardiol 1993;21(suppl A):158A.
18. Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974;47: 211-8.
19. Hindmarch I. Psychomotor functions and psychoactive drugs. In: Lader M, Richens A, editors. Methods in clinical pharmacology - central nervous system. London: MacMillan; 1981. p. 29-50.
20. 1D-receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose range finding study. Neurology 1996;46:522-6.
21. Ingall TJ, McCleaod JG, O'Brien PC. The effect of aging on autonomic nervous system function. Aust NZ J Med 1990;20:570-7.
22. O'Brien IA, O'Hare P, Corrall RJ. Heart rate variability in healthy subjects: effect of age and the derivation of normal ranges for tests of autonomic function. Br Heart J 1986;55:348-54.
23. 1D-agonist 311C90, from a study of the intensity dependence of the cortical auditory evoked potential [abstract]. Eur J Neurol 1996;3(suppl 5):70.
24. Lacey LF, Hussey EK, Fowler PA. Single dose pharmacokinetics of sumatriptan in healthy volunteers Eur J Clin Pharmacol 1995;47:543-8.
25. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50:222-39.
26. Guengerich FP. Inhibition of oral contraceptive steroid-metabolizing enzymes by steroids and drugs. Am J Obstet Gynecol 1990;163:2159-63.
27. Catteau A, Bechtel YC, Poisson N, Bechtel PR, Bonaïti-Piellie C. A population and family study of CYP1A2 using caffeine urinary metabolites. Eur J Clin Pharmacol 1995;47:423-30.
28. Back DJ, Orme MLE. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 1990;18:472-84.
29. Walle T, Walle K, Cowart TD, Conradi EC. Pathway selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther 1989;46:257-63.
30. Gilmore DA, Gal J, Gerber JG, Nies AS. Age and gender influence the stereoselective pharmacokinetics of propranolol. J Pharmacol Exp Ther 1992;261:1181-6.
31. George J, Byth K, Farrell GC. Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem Pharmacol 1995;50:727-30.